Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Oncolytics Biotech Inc. (T.ONC) had Stock-Based Compensation of 3.15M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-9.40M |
|
-- |
|
-- |
|
-- |
|
-9.85M |
|
-- |
|
-9.20M |
|
-9.20M |
|
-9.40M |
|
-9.40M |
|
-9.40M |
|
-9.40M |
|
-9.85M |
|
-9.69M |
|
95.86M |
|
95.86M |
|
-0.09 |
|
-0.09 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
7.70M |
|
-- |
|
-- |
|
-- |
|
11.55M |
|
-3.86M |
|
-3.86M |
|
-3.86M |
|
108.02M |
|
| Cash Flow Statement Financials | |
-20.41M |
|
-0.01M |
|
14.33M |
|
11.24M |
|
5.28M |
|
-5.96M |
|
|
Stock-Based Compensation |
3.15M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.12 |
|
-- |
|
-- |
|
-0.11 |
|
-0.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.42M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
243.78% |
|
243.78% |
|
-122.15% |
|
270.09% |
|
-0.05 |
|
-0.21 |
|
-0.21 |
|